Work

A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.e13600

Authors: Razelle Kurzrock, Jean-Yves Blay, Binh Bui Nguyen, Andrew J. Wagner, Robert G. Maki, Gary K. Schwartz, Amita Patnaik, Lia Gore, Lin Wu, Lyubomir T Vassilev, Michelle Ding, David Geho, Jianguo Zhi, Steven Middleton, Gwen L. Nichols

Institutions: The University of Texas MD Anderson Cancer Center, Centre Léon Bérard, Institut Bergonié, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, South Texas Accelerated Research Therapeutics, University of Colorado Cancer Center

Language: English

Topic: Cancer-related Molecular Pathways

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2600173499

Cites:

Cited by: 30

Related to: 10